Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis

Invest In Intelligence That DeliversEXTON, Pa., Nov. 29, 2017 /PRNewswire/ — At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, a figure on par with uptake of Taltz at a similar post-launch fielding time. Current users of the IL-23 inhibitor cite that they…

TravelWireNews Chatroom for Readers (join us)

%d bloggers like this: